Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

The 2-drug regimen dolutegravir + lamivudine was noninferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA <50 copies/mL in treatment-naive adults in the 48-week primary analysis of the GEMINI trials. We present results from the prespecified 96-week secondar...

Descripción completa

Detalles Bibliográficos
Autores principales: Cahn, Pedro, Madero, Juan Sierra, Arribas, José R., Antinori, Andrea, Ortiz, Roberto, Clarke, Amanda E., Hung, Chien-Ching, Rockstroh, Jürgen K., Girard, Pierre-Marie, Sievers, Jörg, Man, Choy Y., Urbaityte, Rimgaile, Brandon, Daisy J., Underwood, Mark, Tenorio, Allan R., Pappa, Keith A., Wynne, Brian, Gartland, Martin, Aboud, Michael, van Wyk, Jean, Smith, Kimberly Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043729/
https://www.ncbi.nlm.nih.gov/pubmed/31834000
http://dx.doi.org/10.1097/QAI.0000000000002275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043729/
https://www.ncbi.nlm.nih.gov/pubmed/31834000
http://dx.doi.org/10.1097/QAI.0000000000002275

Ejemplares similares